+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06517953

Phase II Study of Befotertinib and Icotinib as First Treatment for Adults With Advanced or Metastatic Non-Small Cell Lung Cancer Having Rare EGFR Mutations

Led by Sun Yat-sen University · Updated on 2024-07-25

23

Participants Needed

1

Research Sites

73 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the combination of two targeted drugs, Befotertinib and Icotinib, as a first-line treatment for people with locally advanced or metastatic Non-Small Cell Lung Cancer NSCLC that has uncommon EGFR mutations. This Phase II study aims to better understand how this drug combination works in patients who have not yet received systemic treatment for advanced NSCLC. The study focuses on specific rare EGFR mutations, including exon 18 G719X, S768I in exon 20, and L861Q in exon 21. Participants will receive oral doses of Icotinib 125 mg three times daily along with Befotertinib 100 mg once daily until their disease progresses or they meet criteria to stop treatment. The study does not include a placebo group and does not use blinding. Patients previously treated with EGFR-TKIs or systemic therapies for advanced NSCLC are not eligible. During the study, participants will be monitored for treatment response, including the objective response rate over 24 months, progression-free survival and disease control rate over 12 months, and overall survival at 24 months. Evaluations will include tumor measurements based on RECIST criteria, performance status assessments, and safety monitoring. The total duration and follow-up will vary based on individual patient progress and treatment response.

CONDITIONS

Brief Title

Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations

Research Team

X

Xue Hou, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here